Integrated Diagnostics (OTCMKTS:IDGXF – Get Free Report) and Illumina (NASDAQ:ILMN – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Analyst Ratings
This is a summary of current ratings and target prices for Integrated Diagnostics and Illumina, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integrated Diagnostics | 0 | 0 | 0 | 0 | 0.00 |
| Illumina | 2 | 6 | 8 | 1 | 2.47 |
Illumina has a consensus target price of $188.40, suggesting a potential upside of 0.06%. Given Illumina’s stronger consensus rating and higher probable upside, analysts plainly believe Illumina is more favorable than Integrated Diagnostics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Integrated Diagnostics | N/A | N/A | N/A |
| Illumina | 18.36% | 29.84% | 12.17% |
Valuation & Earnings
This table compares Integrated Diagnostics and Illumina”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integrated Diagnostics | N/A | N/A | N/A | N/A | N/A |
| Illumina | $4.49 billion | 6.33 | $850.00 million | $5.36 | 35.13 |
Illumina has higher revenue and earnings than Integrated Diagnostics.
Insider & Institutional Ownership
89.4% of Illumina shares are held by institutional investors. 2.9% of Illumina shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Illumina beats Integrated Diagnostics on 10 of the 10 factors compared between the two stocks.
About Integrated Diagnostics
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, including positron emission tomography computed tomography (PET-CT), magnetic resonance imaging (MRI), computed tomography (CT), mammography, ultrasound, x-ray, electromyography (EMG), electroencephalography, electroencephalogram (EEG), and electrocardiogram (ECG), as well as operates cath lab facilities. It operates in Egypt, Sudan, Jordan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.
About Illumina
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
Receive News & Ratings for Integrated Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
